Products - Head and neck cancers | Topic | NICE

Showing 10 products

Date | Title

Status: PublishedRemove ‘Status: Published’ filter

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA736)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 October 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Dinutuximab beta for treating neuroblastoma (TA538)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2018
Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over (NG36)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
6 June 2018
Published:
10 February 2016
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Improving outcomes in head and neck cancers (CSG6)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
24 November 2004
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Head and neck cancer (QS146)
Product type:
Quality standard
Published:
3 March 2017